2,884 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Bigelow Investment Advisors LLC

Bigelow Investment Advisors LLC acquired a new position in Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,884 shares of the company’s stock, valued at approximately $200,000.

Several other institutional investors have also added to or reduced their stakes in NVO. GQG Partners LLC raised its holdings in shares of Novo Nordisk A/S by 74.7% in the fourth quarter. GQG Partners LLC now owns 12,994,533 shares of the company’s stock worth $1,117,790,000 after buying an additional 5,556,460 shares during the period. Raymond James Financial Inc. purchased a new stake in Novo Nordisk A/S in the fourth quarter worth $404,910,000. Loomis Sayles & Co. L P lifted its position in shares of Novo Nordisk A/S by 34.2% during the fourth quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company’s stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the last quarter. Nuveen Asset Management LLC boosted its stake in shares of Novo Nordisk A/S by 73.2% during the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company’s stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the period. Finally, Two Sigma Investments LP bought a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $158,657,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research analyst reports. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. Hsbc Global Res raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating for the company. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, March 13th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $74.03 on Thursday. The firm has a market cap of $332.19 billion, a price-to-earnings ratio of 21.90, a PEG ratio of 1.33 and a beta of 0.66. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The company’s 50 day moving average is $67.98 and its 200 day moving average is $79.17.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. The business had revenue of $11.87 billion for the quarter. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.